Why Spring COPD Exacerbation Demand Pulse Oximeter Monitoring？
- viatomtechnology
- 2 days ago
- 6 min read
Introduction
As winter turns to spring, temperature swings and circulating viruses put COPD patients at high risk. What if the changing of seasons didn't have to mean more COPD exacerbations?
The answer lies in moving from reactive treatment to proactive data by integrating continuous pulse oximeter monitoring with BiPAP machine therapy in COPD management to bridge critical monitoring gaps.
Read on to find out how wearable pulse oximeters can improve BiPAP efficiency and reduce COPD emergencies.
Why spring season demand a COPD management upgrade
COPD is a progressive, irreversible disease that causes breathing difficulties, often worsening over time[1]. For decades, clinicians have approached winter as the “high-risk season” for COPD severity due to cold air constricting airways, indoor heating reducing humidity, and respiratory viruses circulating widely.
But here's what the latest research reveals: SPRING is just as dangerous in COPD exacerbation.
A 2024 study published in ERJ Open Research found something unexpected: in the post-pandemic landscape, spring admission rates due to acute exacerbations of COPD (AECOPD) (34.7%) actually surpassed those in winter (15.8%). Viral triggers didn't disappear when the weather warmed[2]. A large number of patients may still seek hospital COPD exacerbation treatment during warmer months, while outpatient clinics are often stretched thin.
Therefore, this seasonal pattern highlights the importance of enhanced out-of-clinic home monitoring to identify abnormalities in COPD treatment before the event becomes an unavoidable hospital visit.
How is COPD treated now?
COPD treatment aims to optimize symptom control and enhance overall well-being for individuals with COPD. It follows a stepwise approach, typically including:
Stopping smoking – the most important thing you can do
Inhalers and tablets – to relieve symptoms and help make breathing easier
Pulmonary rehabilitation – a specialised programme of exercise and education
Non-invasive ventilation (NIV) – to help improve blood gas outcomes
Surgery or lung transplant – reserved for a small number of severe patients
When to consider a BiPAP Machine for COPD
Bi-level Positive Airway Pressure (BiPAP) for NIV is commonly adopted to treat exacerbation of COPD. Unlike a CPAP machine's single pressure, a BiPAP machine delivers two levels: higher pressure during inhalation (IPAP) to help draw air in, and lower pressure during exhalation (EPAP) to help clear carbon dioxide.
BiPAP is prescribed in the following key scenarios:
Acute exacerbations (PaCO₂ >45 mmHg or pH <7.3)
Substantial respiratory distress (respiratory rate >30/min)
Severe COPD with chronic hypercapnia (PaCO₂ ≥52 mmHg)
Nocturnal desaturation (<88%)
Use of the BiPAP machine with usual care has been proven to reduce mortality by 46%, decrease the need for intubation by 64%, and shorten hospitalization by more than 3 days[3]. Modern home BiPAP machines are now portable and suitable for out-of-clinic use, allowing patients to receive treatment supported by reimbursement.
Why BiPAP machines and clinic visits aren't enough
COPD is treatable, especially with BiPAP devices. In practice, effective COPD therapy, however, is hindered by several monitoring challenges:
The Missing Data
COPD is a dynamic condition requiring continuous observation, because the speed of progression varies from person to person. However, normal monitoring ends at the clinic door, leaving a critical data gap. Patients spend most of their time at home, where early warning signs like subtle nocturnal oxygen dips go unrecorded. Without continuous out-of-hospital data, clinicians are forced to make decisions relying on patient recall—a method proven to miss up to two-thirds of COPD exacerbations, and more than one-quarter of the COPD exacerbations never get reported at all[4].
The Silent Aggravation
The COPD exacerbations often go unnoticed. A 2025 Nature study has confirmed that physiological deterioration can begin days before COPD symptoms surface[5]. Another study highlights a well-documented phenomenon of symptom under-reporting, particularly among long-term COPD patients who normalize gradual decline as “just part of the disease.” This adaptation means patients delay seeking help until symptoms become unbearable[6].
Studies show that each day of delay in reporting increases recovery time by 0.42 days, and patients who turn to emergency departments more than 24 hours after symptom onset present double the odds of hospitalization[7], driving up clinical burden and healthcare costs.
The Lagged Intervention
Current clinic checks are missing the window for early COPD intervention in the following two distinct delays:
System Delay: A 2021 Nature study found that patients seeking outpatient care during exacerbations frequently encountered wait times that precluded being seen in primary care[8]. The passive healthcare model cannot keep pace with acute events.
Patient Delay: A 2022 Nature study demonstrated that waiting is a typical response of patients to new exacerbations to see if symptoms would subside, hoping to avoid care-seeking. Many waited until COPD symptoms felt “bad enough”[9]. Therefore, by the time they seek help, the intervention is usually too late.
As a result, between long queue times and a “wait it out” mindset, the critical window for early intervention closes.
Why integrate pulse oximeter monitoring into COPD Treatment
A 2018 study observed significant SpO2 declines a full 7 days before COPD exacerbation, with increased daily desaturation events during that window[10], indicating that warning signs like desaturation events during that window were entirely invisible without monitoring.
A 2025 comprehensive review in the Journal of Clinical Medicine reinforced the opinion, highlighting that self-management interventions and telehealth programs help patients identify COPD exacerbations before deterioration becomes severe[11].
Among various home-monitoring devices, wearable pulse oximeters are proven as effective tool for COPD management. A pulse oximeter uses red and infrared light to measure SpO2 non-invasively. It is affordable, widely available, and supported by mature reimbursement, making it practical for primary care.
With remote pulse oximetry, clinicians can:
Monitor BiPAP effectiveness overnight objectively
Track daily SpO2 trends between clinic visits
Detect COPD deterioration before patients feel symptoms
Therefore, SpO2 monitoring by pulse oximeter can successfully predict COPD exacerbations and transform reactive care into proactive management.
What makes the Viatom pulse oximeter your priority choice
Viatom has spent years developing wearable pulse oximeters now trusted by healthcare providers worldwide for chronic lung disease management. Here is why they stand out:
1. Real-time Patient Monitoring
With high sampling frequency and long battery life, Viatom delivers accurate SpO2 readings and trends, which give clinicians objective data to adjust BiPAP pressures and track respiratory disease progression, without guessing based on patient recall.
Viatom offers intuitive designs for every clinic's needs:
Fingertip oximeter for quick spot checks
Ring oximeter for continuous, comfortable wear
Wrist oximeter for extended consecutive overnight tracking
1. Proactive Remote Monitoring
Seamless connection of Viatom pulse oximeters enables continuous tele-surveillance of high-risk COPD patients, especially necessary during seasonal change. The data synchronization and long-term history storage allow:
Monitoring key vital signs remotely
Managing patients with varying COPD stages
Eliminating the need for frequent in-clinic visits.
2. Predictive Alerting
Low oxygen saturation is not just a symptom—it’s often a predictor[10]. Viatom wearable pulse oximeters with customizable vibration alerts provide patients with an immediate trigger for intervention, potentially stopping a mild dip from becoming a serious hospitalization.
3. Better Patient Adherence
When COPD patients see their oxygen levels stabilize thanks to BiPAP, compliance improves naturally. Viatom pulse oximeters are gaining industry recognition with a patient-friendly design and a high compliance rate, with features like:
Clear display of SpO2 for real-time readings
ViHealth app showing therapy impact
Comfortable designs that encourage overnight use
Conclusion
The winter-to-spring transition is a high-risk period for COPD patients, worsened by the gap between clinic visits, where early warning signs appear but go unnoticed. For primary care clinics, adopting wearable pulse oximeters together with BiPAP machines can effectively close this gap by continuous monitoring.
Viatom pulse oximeters deliver what primary care truly needs: lab-grade accuracy, remote monitoring, wireless connectivity, predictive alerts, and patient-friendly designs. Consider integrating Viatom pulse oximeters for improved clinical outcomes every season.
Contact us to learn more.
References:
[1] COPD - What Is COPD? (2024)
[2] Post-pandemic seasonal dynamics of hospitalised COPD exacerbations and aetiologies in the COPD population (2024)
[3] Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease (2017)
[4] Assessing the Usefulness of the Prevexair Smartphone Application in the Follow-Up High-Risk Patients with COPD (2021)
[5] Impact of seasonal biometeorological conditions and particulate matter on asthma and COPD hospital admissions (2025)
[6] Characterisation of COPD heterogeneity in the ECLIPSE cohort (2010)
[7] Understanding the Gaps in the Reporting of COPD Exacerbations by Patients: A Review (2024)
[8] Analysis of diagnostic delay and its influencing factors in patients with chronic obstructive pulmonary disease: a cross-sectional study (2021)
[9] Care-seeking and delay of care during COPD exacerbations (2022)
[10] A pilot study of daily telemonitoring to predict acute exacerbation in chronic obstructive pulmonary disease (2018)
[11] Early Identification of Exacerbations in Patients with Chronic Obstructive Pulmonary Disease (COPD) (2025)
